The global BELVIQ market is anticipated to grow significantly over the forecast period. BELVIQ, a product of Arena Pharmaceuticals GmbH. is an FDA-approved prescription weight-loss medication that helps overweight and obese adults lose weight and keep it off. BELVIQ has to be taken along with a prescribed diet and exercise program suggested by the physician. It Targets a hunger receptor in the brain, consequently enabling the user to feel satisfied with less food. FDA clinical trials exhibited the effectiveness of the drug to achieve weight loss as well as improve health risk factors, such as high blood sugar, high blood pressure, and high cholesterol levels.
The obesity market has witnessed a revival after more than a decade with the advent of various innovative therapies that are expected to address the issue. This includes the use of combination therapies that regulate appetite control and simultaneously targeting multiple pathways, as well as new mechanisms of action having novel entities. The BELVIQ market is expected to experience substantial growth over the next decade due to this growing pipeline of late-stage drugs. The increased base of the overweight and obese population that requires pharmacological intervention is one of the biggest drivers for the growth of this market. Physicians resort to earlier treatment as a proactive measure to curtail disease progression resulting in the frequent prescription of pharmacological therapy. This is expected to further boost the market growth. Greater responsibility for reimbursement on third-party payers allows greater access to medications to patients. The manufacturer has released safety information that users have to go through before consuming this drug which contains a list of side-effects caused by it. These side effects are expected to restraint the growth of this market. Some of the side effects caused include confusion, hallucinations, agitation, inability to pay attention, inability to retain memory, suicidal thoughts or other changes in mental status, uncontrolled muscle spasms, coordination problems, restlessness, muscle twitching, stiff muscles, racing or fast heartbeat, sweating, high or low blood pressure, diarrhea, fever, nausea, vomiting, heart valve problems, low blood sugar, slow heartbeats, decrease in blood cell count, increase in prolactin and others. Consumption of BELVQ is not advised during pregnancy as it may cause harm to the baby. Additionally, BELVIQ may cause drug interaction with other drugs used for countering depression, migraines, and other medical conditions. Furthermore, for people suffering from diabetes, it produces symptoms such as low blood sugar, headache, back pain, cough, and fatigue.
BELVIQ is not yet approved in any of the European markets, Brazil, Canada, and Japan. It is not expected to reach the Brazilian market until 2016, the Canadian market until 2017, and the European market until 2018.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.